Literature DB >> 9918138

Detection and characterization of novel polymorphisms in the CYP2E1 gene.

K S Fairbrother1, J Grove, I de Waziers, D T Steimel, C P Day, C L Crespi, A K Daly.   

Abstract

To investigate whether interindividual variation in CYP2E1 levels can be explained by genetic polymorphism, we analysed DNA samples from 40 healthy individuals by single-strand conformational polymorphism analysis for polymorphisms in the CYP2E1 coding sequence and promoter region. DNA sequencing of samples showing mobility shifts on single-strand conformational polymorphism detected polymorphisms at positions -316 (A to G), -297 (T to A), -35 (G to T), 1107 (G to C; intron 1), 4804 (G to A Val179Ile; exon 4) and 10157 (C to T; exon 8). All individuals positive for either A(-316)G, G(-35)T, G(4804)A or the previously described RsaI polymorphism at -1019 were also positive for T(-297)A, which had the highest allele frequency of the observed polymorphisms (0.20). A(-316)G, G(-35)T and G(4804)A were detected at allele frequencies of 0.022, 0.052 and 0.013, respectively. The functional significance of the upstream polymorphisms was examined by preparing constructs of positions -549 to +3 of CYP2E1 containing the observed combinations of the polymorphisms fused to luciferase reporter genes and transfecting HepG2 cells. For the G(-35)T/T(-297)A construct, a 1.8-fold increase in luciferase activity compared with the wild-type sequence (P = 0.06) and 2.5-fold compared with T(-297)A only (P = 0.025) was observed. No significant difference in activity was observed between the other constructs. The significance of the predicted Val179Ile base change from G(4804)A was determined by expression of the wild-type and mutated full length cDNAs in lymphoblastoid cells. No significant difference in kinetic constants for chlorzoxazone hydroxylation between mutant and wild-type was observed. In summary, this study demonstrated six novel CYP2E1 polymorphisms, including three upstream of the promoter, but with the possible exception of G(-35)T, none appeared to be of functional significance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9918138     DOI: 10.1097/00008571-199812000-00011

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  16 in total

Review 1.  Candidate gene case-control association studies: advantages and potential pitfalls.

Authors:  A K Daly; C P Day
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population.

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Saori Kawauchi; Shoko Higuchi; Chie Ogawa; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

Review 3.  The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine.

Authors:  Hermann M Bolt; Peter H Roos; Ricarda Thier
Journal:  Int Arch Occup Environ Health       Date:  2003-03-01       Impact factor: 3.015

4.  CYP2E1 gene rs6413420 polymorphism was first found in the Bouyei ethnic group of China.

Authors:  Wei Liu; Li Zhou; Hongju Wang; Bo Zheng; Desheng Wu; Xifei Yang; Jianjun Liu
Journal:  Int J Clin Exp Med       Date:  2014-10-15

5.  Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates.

Authors:  Patrick R Porubsky; Kathleen M Meneely; Emily E Scott
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

6.  Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.

Authors:  Lena Ernstgård; Margareta Warholm; Gunnar Johanson
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

7.  Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line.

Authors:  Jian Zhuge; Ye Luo; Ying-Nian Yu
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

8.  Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population.

Authors:  H Niazi Shahabi; L Westberg; J Melke; A Håkansson; A Carmine Belin; O Sydow; L Olson; B Holmberg; H Nissbrandt
Journal:  J Neural Transm (Vienna)       Date:  2009-04-21       Impact factor: 3.575

Review 9.  Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.

Authors:  Magnus Ingelman-Sundberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-22       Impact factor: 3.000

10.  Biomarkers of human exposure to acrylamide and relation to polymorphisms in metabolizing genes.

Authors:  Nur Duale; Thomas Bjellaas; Jan Alexander; Georg Becher; Margaretha Haugen; Jan Erik Paulsen; Henrik Frandsen; Pelle Thonning Olesen; Gunnar Brunborg
Journal:  Toxicol Sci       Date:  2009-01-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.